Apremilast Tablets

Project Image
Thumb Image

Therapeutic Indication

Moderate to severe plaque psoriasis
Psoriatic arthritis
Oral anti-inflammatory therapy for chronic autoimmune conditions
+91 85919 78885

Apremilast

Tablet

Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. It reduces inflammation by modulating intracellular signaling pathways and cytokine production.

Speciality Dermatology | Rheumatology | Immunology
Tags Psoriasis | Psoriatic Arthritis | PDE4 Inhibitor | Anti-inflammatory
Strength
  • 10 mg
  • 20 mg
  • 30 mg
Packing Size
  • 10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Apremilast inhibits phosphodiesterase 4 (PDE4), leading to increased intracellular cAMP levels. This results in downregulation of pro-inflammatory cytokines (TNF-α, IL-17, IL-23) and upregulation of anti-inflammatory mediators, reducing inflammation in psoriasis and psoriatic arthritis.

Pharmacokinetics

  • Absorption: Rapid oral absorption; peak plasma concentration in ~2.5 hours
  • Distribution: Protein binding ~68%
  • Metabolism: Hepatic via CYP3A4 (minor CYP1A2, CYP2A6 involvement)
  • Half-life: ~6–9 hours
  • Excretion: ~58% via urine, ~39% via feces

Side Effects

  • Diarrhea
  • Nausea
  • Headache
  • Weight loss
  • Depression (rare)

Contraindication

  • Hypersensitivity to Apremilast
  • Pregnancy (risk of fetal harm)
  • Severe renal impairment (dose adjustment required)

Interaction

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): ↓ Apremilast efficacy
  • Other immunosuppressants: additive effects

    • Warning and Precautions

    • Monitor for depression and suicidal ideation
    • Monitor weight regularly
    • Adjust dose in renal impairment
    • Not recommended in pregnancy or breastfeeding

    Dosage

    As directed by the Physician.